Dietary n-3 PUFA and CVD: A review of the evidence

Proceedings of the Nutrition Society

Volumn 73, Issue 1, 2014, Pages 57-64

  Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiometabolic risk factors; Cardiovascular risk factors; Fish; Fish oils; Human studies; n 3 Fatty acids

Indexed keywords

ANIMALS; CARDIOVASCULAR DISEASES; DIET; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FISH OILS; FISHES; FOOD HABITS; HUMANS;

FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BRAIN ISCHEMIA; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEPRESSED BLOOD PRESSURE; FIBRINOLYSIS; GLYCEMIC CONTROL; HEART FAILURE; HEART FIBRILLATION; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID PEROXIDATION; MEDIATOR RELEASE; META ANALYSIS (TOPIC); OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; SUDDEN DEATH; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 84893906691     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665113003583     Document Type: Article

References (81)

1. Schmidt EB, Arnesen H, de Caterina R et al. (2005) Marine n-3 polyunsaturated fatty acids and coronary heart disease - Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 115, 163-170.
2. Schmidt EB, Arnesen H, Christensen JH et al. (2005) Marine n-3 polyunsaturated fatty acids and coronary heart disease - Part II: clinical trials and recommendations. Thromb Res 115, 257-262.
3. Mori TA & Beilin LJ (2001) Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 12, 11-17.
4. Mozaffarian D & Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58, 2047-2067.
5. Appel LJ, Miller ER, Seidler AJ et al. (1993) Does supplementation of diet with fish-oil reduce blood-pressure - a metaanalysis of controlled clinical-trials. Arch Intern Med 153, 1429-1438.
6. Geleijnse JM, Giltay EJ, Grobbee DE et al. (2002) Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20, 1493-1499.
7. Mori TA, Burke V & Beilin LJ (2007) Dietary fats and blood pressure. In Comprehensive Hypertension. Section I: Epidemiology, pp. 77-88 [GYH Lip & JE Hall, editors]. Philadelphia, USA: Elsevier, ISBN-13: 978-0-323-03961-1.
8. Morris MC, Sacks F & Rosner B (1993) Does fish-oil lower blood-pressure - a metaanalysis of controlled trials. Circulation 88, 523-533.
9. McVeigh GE, Brennan GM, Cohn JN et al. (1994) Fish-oil improves arterial compliance in non-insulin-dependent diabetes-mellitus. Arterioscler Thromb 14, 1425-1429.
10. Nestel P, Shige H, Pomeroy S et al. (2002) The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 76, 326-330.
11. Chin JP (1994) Marine oils and cardiovascular reactivity. Prostaglandins Leukot Essent Fatty Acids 50, 211-222.
12. Mori TA, Watts GF, Burke V et al. (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102, 1264-1269.
13. Harris WS (1996) n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 31, 243-252.
14. Harris WS (1997) n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65, Suppl. 5, 1645S-1654S.
15. Calder PC (2001) Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36, 1007-1024.
16. Knapp HR (1997) Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 65, S1687-S1698.
17. Mori TA & Beilin LJ (2004) Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 6, 461-467.
18. Calder PC (2012) The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 56, 1073-1080.
19. Serhan CN & Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 5922-5943.
20. Mas E, Woodman RJ, Burke V et al. (2010) The omega-3 fatty acids EPA and DHA decrease plasma F (2)-isoprostanes: results from two placebo-controlled interventions. Free Radic Res 44, 983-990.
21. Mori TA & Woodman RJ (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9, 95-104.
22. Wang CC, Harris WS, Chung M et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alphalinolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84, 5-17.
23. Bucher HC, Hengstler P, Schindler C et al. (2002) n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298-304.
24. He K, Song YQ, Daviglus ML et al. (2004) Accumulated evidence on fish consumption and coronary heart disease mortality - A meta-analysis of cohort studies. Circulation 109, 2705-2711.
25. Whelton SP, He J, Whelton PK et al. (2004) Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 93, 1119-1123.
26. Levitan EB, Wolk A & Mittleman MA (2009) Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 30, 1495-1500.
27. Mozaffarian D, Bryson CL, Lemaitre RN et al. (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 2015-2021.
28. He K, Song YQ, Daviglus ML et al. (2004) Fish consumption and incidence of stroke - A meta-analysis of cohort studies. Stroke 35, 1538-1542.
29. Xun P, Qin B, Song Y et al. (2012) Fish consumption and risk of stroke and its subtypes: accumulative evidence from a meta-analysis of prospective cohort studies. Eur J Clin Nutr 66, 1199-1207.
30. Burr ML, Gilbert JF, Holliday RM et al. (1989) Effects of changes in fat, fish, and fiber intakes on death and myocardial reinfarction - diet and reinfarction trial (dart). Lancet 2, 757-761.
31. Valagussa F, Franzosi MG, Geraci E et al. (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447-455.
32. Tavazzi L, Maggioni AP, Marchioli R et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223-1230.
33. Yokoyama M, Origasa H, Matsuzaki M et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet 369, 1090-1098.
34. Bosch J, Gerstein HC, Dagenais GR et al. (2012) n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. New Engl J Med 367, 309-318.
35. Mozaffarian D, Marchioli R, Macchia A et al. (2012) Fish oil and postoperative atrial fibrillation the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. Jama-J Am Med Assoc 308, 2001-2011.
36. Roncaglioni MC, Tombesi M, Avanzini F et al. (2013) n-3 fatty acids in patients with multiple cardiovascular risk factors. New Engl J Med 368, 1800-1808.
37. Dickinson HO, Mason JM, Nicolson DJ et al. (2006) Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24, 215-233.
38. Dokholyan RS, Albert CM, Appel LJ et al. (2004) Trial of omega-3 fatty acids for prevention of hypertension. Am J Cardiol 93, 1041-1043.
39. Cobiac L, Nestel PJ, Wing LMH et al. (1992) A lowsodium diet supplemented with fish oil lowers bloodpressure in the elderly. J Hypertens 10, 87-92.
40. Singer P, Melzer S, Goschel M et al. (1990) Fish oil amplifies the effect of propranolol in mild essentialhypertension. Hypertension 16, 682-691.
41. Lungershausen YK, Abbey M, Nestel PJ et al. (1994) Reduction of blood-pressure and plasma triglycerides by omega-3-fatty-acids in treated hypertensives. J Hypertens 12, 1041-1045.
42. Bao DQ, Mori TA, Burke V et al. (1998) Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 32, 710-717.
43. Mori TA, Bao DQ, Burke V et al. (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253-260.
44. Grimsgaard S, Bonaa KH, Hansen JB et al. (1998) Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 68, 52-59.
45. Woodman RJ, Mori TA, Burke V et al. (2002) Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 76, 1007-1015.
46. Mozaffarian D, Geelen A, Brouwer IA et al. (2005) Effect of fish oil on heart rate in humans - A meta-analysis of randomized controlled trials. Circulation 112, 1945-1952.
47. Pase MP, Grima NA & Sarris J (2011) Do long-chain n-3 fatty acids reduce arterial stiffness' A meta-analysis of randomised controlled trials. Brit J Nutr 106, 974-980.
48. Christensen JH (2003) n-3 Fatty acids and the risk of sudden cardiac death - emphasis on heart rate variability. Dan Med Bull 50, 347-367.
49. Christensen JH & Schmidt EB (2001) n-3 Fatty acids and the risk of sudden cardiac death. Lipids 36, S115-S118.
50. Xin W, Wei W & Li XY (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 926-935.
51. Leaf A, Kang JX, Xiao YF et al. (2003) Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107, 2646-2652.
52. Mori TA, Bao DQ, Burke V et al. (1999) Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr 70, 817-825.
53. Mori TA, Burke V, Puddey IB et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 1085-1094.
54. Harris WS & Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides' Curr Opin Lipidol 17, 387-393.
55. Cussons AJ, Watts GF, Mori TA et al. (2009) Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 94, 3842-3848.
56. Woodman RJ, Mori TA, Burke V et al. (2003) Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 26, 253.
57. Hulthe J, Bokemark L, Wikstrand J et al. (2000) The metabolic syndrome, LDL particle size, and atherosclerosis - the atherosclerosis and insulin resistance (AIR) study. Arterioscler Throm Vas 20, 2140-2147.
58. Lahdenpera S, Syvanne M, Kahri J et al. (1996) Regulation of low-density lipoprotein particle sire distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39, 453-461.
59. Chan DC, Watts GF, Mori TA et al. (2002) Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 32, 429-436.
60. Friedberg CE, Janssen MJFM, Heine RJ et al. (1998) Fish oil and glycemic control in diabetes - A meta-analysis. Diabetes Care 21, 494-500.
61. Hartweg J, Perera R, Montori V et al. (2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Db Syst Rev. Issue 1. Article number CD 003205. doi: 10.1002/14651858.CD003205. pub 2.
62. Montori VM, Farmer A, Wollan PC et al. (2000) Fish oil supplementation in type 2 diabetes - A quantitative systematic review. Diabetes Care 23, 1407-1415.
63. Mori TA, Beilin LJ, Burke V et al. (1997) Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 17, 279-286.
64. Kristensen SD, Iversen AMB & Schmidt EB (2001) n-3 Polyunsaturated fatty acids and coronary thrombosis. Lipids 36, S79-S82.
65. De Caterina R, Liao JK & Libby P (2000) Fatty acid modulation of endothelial activation. Am J Clin Nutr 71, 213s-223s
66. Bannenberg G, Arita M & Serhan CN (2007) Endogenous receptor agonists: resolving inflammation. Sci World J 7, 1440-1462.
67. Serhan CN (2005) Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 8, 115-121.
68. Serhan CN (2005) Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105, 7-21.
69. Serhan CN, Brain SD, Buckley CD et al. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21, 325-332.
70. Serhan CN & Chiang N (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13, 632-640.
71. Ji RR, Xu ZZ, Strichartz G et al. (2011) Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 34, 599-609.
72. Serhan CN, Chiang N & Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349-361.
73. Tabas I (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10, 36-46.
74. Mas E, Croft KD, Zahra P et al. (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 1476-1484.
75. Thies F, Garry JMC, Yaqoob P et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477-485.
76. Mori TA, Dunstan DW, Burke V et al. (1999) Effect of dietary fish and exercise training on urinary F2-isoprostane excretion in non-insulin-dependent diabetic patients. Metabolism 48, 1402-1408.
77. Mori TA, Woodman RJ, Burke V et al. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treatedhypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772-781.
78. Mori TA, Puddey IB, Burke V et al. (2000) Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep 5, 45-46.
79. Milne GL, Yin HY, Hardy KD et al. (2011) Isoprostane Generation and Function. Chem Revi 111, 5973-5996.
80. Barden AE, Mori TA, Dunstan JA et al. (2004) Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic Res 38, 233-239.
81. Lloyd-Jones DM, Hong YL, Labarthe D et al. (2010) Defining and setting national goals for cardiovascular health promotion and disease reduction the American heart association's strategic impact goal through 2020 and beyond. Circulation 121, 586-613.